OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES

$54,827P51FY2010RRNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Paper 38214558 Paper 37693595 Paper 36114169 Paper 36074577 Paper 35445423 Paper 34855621 Paper 34498433 Paper 34437736 Paper 33910220 Paper 33707771 Paper 33529681 Paper 33463551 Paper 33359631 Paper 33338613 Paper 33137689 Paper 33084571 Paper 32951543 Paper 32905842 Paper 32612608 Paper 32580662 Paper 32569766 Paper 32561559 Paper 32332110 Paper 32250460 Paper 31926168 Paper 31904583 Paper 31898839 Paper 31722194 Paper 31643109 Paper 31455727 Paper 31341049 Paper 31080066 Paper 30910223 Paper 30807811 Paper 30778066 Paper 30718403 Paper 30541829 Paper 30502901 Paper 30486918 Paper 30450384 Paper 30295946 Paper 30237074 Paper 30232277 Paper 30178424 Paper 30021123 Paper 29997216 Paper 29987877 Paper 29983703 Paper 29978933 Paper 29929489 Paper 29928280 Paper 29887142 Paper 29777188 Paper 29752749 Paper 29657070 Paper 29614657 Paper 29510099 Paper 29508924 Paper 29454797 Paper 29386136 Paper 29357021 Paper 29345365 Paper 29158413 Paper 29133346 Paper 29065175 Paper 28926189 Paper 28899729 Paper 28862836 Paper 28842187 Paper 28829774 Paper 28819207 Paper 28648500 Paper 28622613 Paper 28483344 Paper 28483199 Paper 28461219 Paper 28377304 Paper 28369850 Paper 28337120 Paper 28289708 Paper 28269776 Paper 28242325 Paper 28215744 Paper 28159893 Paper 28126752 Paper 28093566 Paper 28051083 Paper 28030956 Paper 28027448 Paper 28025095 Paper 27942478 Paper 27931313 Paper 27928002 Paper 27893962 Paper 27880897 Paper 27870344 Paper 27870343 Paper 27861291 Paper 27851926 Paper 27849172

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this project is to identify strategies by which the immunogenicity of AIDS vaccines that are derived from Modified Vaccinia Ankara (MVA)-based viral vectors can be significantly augmented. In this project, we have developed and characterized an MVA-based HIV vaccine, from which several endogenous poxvirus immune-evasion genes have been deleted, that expresses consensus HIV subtype C Gag and Env antigens. This vaccine has been shown to elicit significantly higher levels of HIV-specific CD8 and CD4 T cell responses, as well as HIV envelope-specific antibody responses, as compared to the parental control vector, in MHC-disparate populations of rhesus macaques. Presently ongoing studies with this vaccine include a preclinical trial in rhesus macaques that is designed to test the hypothesis that the immunogenicity of this improved vector may be even further augmented through co-administration with specific toll-like receptor (TLR) -7, and -9 agonists. In addition, analogous recombinant MVA vectors expressing SIV, rather than HIV, antigens are currently being assessed in rhesus macaques for their ability to elicit systemic and mucosal immune responses, as well as protection against mucosal SIVmac239 challenge, following both homologous prime-boost immunization regimens and heterologous prime-boost immunizations with adenoviral vectors. Particularly, in light of recent positive results from the HIV vaccine efficacy trial in Thailand (RV144), the development of highly immunogenic AIDS vaccines from poxvirus vectors remains a high priority for the field.

View original record on NIH RePORTER →